Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.

Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F, Couzi L, Jourde-Chiche N, Chatelet V, Gaisne R, Bertrand D, Bamoulid J, Louis M, Sberro Soussan R, Navarro D, Westeel PF, Frimat L, Colosio C, Thierry A, Rivalan J, Albano L, Arzouk N, Cornec-Le Gall E, Claisse G, Elias M, El Karoui K, Chauvet S, Coindre JP, Rerolle JP, Tricot L, Sayegh J, Garrouste C, Charasse C, Delmas Y, Massy Z, Hourmant M, Servais A, Loirat C, Fakhouri F, Pouteil-Noble C, Peraldi MN, Legendre C, Rondeau E, Le Quintrec M, Frémeaux-Bacchi V.

J Am Soc Nephrol. 2019 Oct 1. pii: ASN.2019040331. doi: 10.1681/ASN.2019040331. [Epub ahead of print]

PMID:
31575699
2.

Immune phenotype predicts new onset diabetes after kidney transplantation.

Ducloux D, Courivaud C, Bamoulid J, Crepin T, Gaiffe E, Laheurte C, Vauchy C, Rebibou JM, Saas P, Borot S.

Hum Immunol. 2019 Sep 9. pii: S0198-8859(19)30284-8. doi: 10.1016/j.humimm.2019.08.006. [Epub ahead of print]

PMID:
31515130
3.

End-Stage Renal Disease-Associated Gut Bacterial Translocation: Evolution and Impact on Chronic Inflammation and Acute Rejection After Renal Transplantation.

Carron C, Pais de Barros JP, Gaiffe E, Deckert V, Adda-Rezig H, Roubiou C, Laheurte C, Masson D, Simula-Faivre D, Louvat P, Moulin B, Frimat L, Rieu P, Mousson C, Durrbach A, Heng AE, Saas P, Ducloux D, Lagrost L, Bamoulid J.

Front Immunol. 2019 Aug 16;10:1630. doi: 10.3389/fimmu.2019.01630. eCollection 2019.

4.

PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study.

Gaiffe E, Crepin T, Bamoulid J, Courivaud C, Büchler M, Cassuto E, Albano L, Chemouny JM, Choukroun G, Hazzan M, Kessler L, Legendre C, Le Meur Y, Ouali N, Thierry A, Anota A, Nerich V, Limat S, Bonnetain F, Vernerey D, Ducloux D.

Trials. 2019 Jun 21;20(1):375. doi: 10.1186/s13063-019-3392-6.

5.

Uraemia-induced immune senescence and clinical outcomes in chronic kidney disease patients.

Crépin T, Legendre M, Carron C, Vachey C, Courivaud C, Rebibou JM, Ferrand C, Laheurte C, Vauchy C, Gaiffe E, Saas P, Ducloux D, Bamoulid J.

Nephrol Dial Transplant. 2018 Sep 6. doi: 10.1093/ndt/gfy276. [Epub ahead of print]

PMID:
30202981
6.

Antithymocytes globulins: Time to revisit its use in kidney transplantation?

Ducloux D, Bamoulid J, Daguindau E, Rebibou JM, Courivaud C, Saas P.

Int Rev Immunol. 2018;37(4):183-191. doi: 10.1080/08830185.2018.1455194. Epub 2018 Aug 6.

PMID:
30081695
7.

ESRD-associated immune phenotype depends on dialysis modality and iron status: clinical implications.

Ducloux D, Legendre M, Bamoulid J, Rebibou JM, Saas P, Courivaud C, Crepin T.

Immun Ageing. 2018 Jul 17;15:16. doi: 10.1186/s12979-018-0121-z. eCollection 2018.

8.

Posttransplant Immune Activation: Innocent Bystander or Insidious Culprit of Posttransplant Accelerated Atherosclerosis.

Ducloux D, Bamoulid J, Crepin T, Rebibou JM, Courivaud C, Saas P.

Cell Transplant. 2017 Sep;26(9):1601-1609. doi: 10.1177/0963689717735404. Review.

9.

Immune reconstitution with two different rabbit polyclonal anti-thymocytes globulins.

Bamoulid J, Crepin T, Gaiffe E, Laheurte C, Moulin B, Frimat L, Rieu P, Mousson C, Durrbach A, Heng AE, Rebibou JM, Saas P, Courivaud C, Ducloux D.

Transpl Immunol. 2017 Dec;45:48-52. doi: 10.1016/j.trim.2017.09.002. Epub 2017 Sep 20.

PMID:
28941751
10.

Antithymocyte globulins in renal transplantation-from lymphocyte depletion to lymphocyte activation: The doubled-edged sword.

Bamoulid J, Crépin T, Courivaud C, Rebibou JM, Saas P, Ducloux D.

Transplant Rev (Orlando). 2017 Jul;31(3):180-187. doi: 10.1016/j.trre.2017.02.004. Epub 2017 Feb 17. Review.

PMID:
28456447
11.

Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects.

Bamoulid J, Staeck O, Crépin T, Halleck F, Saas P, Brakemeier S, Ducloux D, Budde K.

Nephrol Dial Transplant. 2017 Oct 1;32(10):1601-1608. doi: 10.1093/ndt/gfw368. Review.

PMID:
27798202
12.

Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation.

Bamoulid J, Roodenburg A, Staeck O, Wu K, Rudolph B, Brakemeier S, Halleck F, Lehner L, Schönemann C, Lachmann N, Budde K.

Transplantation. 2017 Sep;101(9):2165-2174. doi: 10.1097/TP.0000000000001487.

PMID:
27653301
13.

Immunologic outcome in elderly kidney transplant recipients: is it time for HLA-DR matching?

Halleck F, Khadzhynov D, Liefeldt L, Schrezenmeier E, Lehner L, Duerr M, Schmidt D, Bamoulid J, Lachmann N, Waiser J, Budde K, Staeck O.

Nephrol Dial Transplant. 2016 Dec;31(12):2143-2149. Epub 2016 Jul 1.

PMID:
27369852
14.

Late Persistent Positive EBV Viral Load and Risk of Solid Cancer in Kidney Transplant Patients.

Bamoulid J, Courivaud C, Coaquette A, Crépin T, Carron C, Gaiffe E, Roubiou C, Rebibou JM, Ducloux D.

Transplantation. 2017 Jun;101(6):1473-1478. doi: 10.1097/TP.0000000000001280.

PMID:
27367471
15.

Reversible Fluindione-Induced Chronic Interstitial Nephritis.

Crepin T, Bamoulid J, Courivaud C, Dahmani O, Felix S, Ducloux D.

Case Rep Nephrol. 2016;2016:9818195. doi: 10.1155/2016/9818195. Epub 2016 Apr 5.

16.

Pretransplant thymic function predicts acute rejection in antithymocyte globulin-treated renal transplant recipients.

Bamoulid J, Courivaud C, Crepin T, Carron C, Gaiffe E, Roubiou C, Laheurte C, Moulin B, Frimat L, Rieu P, Mousson C, Durrbach A, Heng AE, Rebibou JM, Saas P, Ducloux D.

Kidney Int. 2016 May;89(5):1136-1143. doi: 10.1016/j.kint.2015.12.044. Epub 2016 Mar 2.

PMID:
27083287
17.

Pre-transplant end-stage renal disease-related immune risk profile in kidney transplant recipients predicts post-transplant infections.

Crepin T, Gaiffe E, Courivaud C, Roubiou C, Laheurte C, Moulin B, Frimat L, Rieu P, Mousson C, Durrbach A, Heng AE, Saas P, Bamoulid J, Ducloux D.

Transpl Infect Dis. 2016 Jun;18(3):415-22. doi: 10.1111/tid.12534. Epub 2016 May 21.

PMID:
27027787
18.

[Immunosuppression and its use in kidney transplantation].

Paliege A, Bamoulid J, Bachmann F, Staeck O, Halleck F, Khadzhynov D, Brakemeier S, Dürr M, Budde K.

Urologe A. 2015 Oct;54(10):1376-84. doi: 10.1007/s00120-015-3909-x. Review. German.

PMID:
26459580
19.

The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy.

Wu K, Budde K, Schmidt D, Neumayer HH, Lehner L, Bamoulid J, Rudolph B.

Clin Transplant. 2016 Feb;30(2):105-17. doi: 10.1111/ctr.12645. Epub 2016 Jan 5.

PMID:
26448478
20.

Need for optimized immunosuppression in elderly kidney transplant recipients.

Lehner LJ, Staeck O, Halleck F, Liefeldt L, Bamoulid J, Budde K.

Transplant Rev (Orlando). 2015 Oct;29(4):237-9. doi: 10.1016/j.trre.2015.08.001. Epub 2015 Aug 15. Review.

PMID:
26411381
21.

Advances in pharmacotherapy to treat kidney transplant rejection.

Bamoulid J, Staeck O, Halleck F, Dürr M, Paliege A, Lachmann N, Brakemeier S, Liefeldt L, Budde K.

Expert Opin Pharmacother. 2015;16(11):1627-48. doi: 10.1517/14656566.2015.1056734. Review.

PMID:
26159444
22.

[Clinical consequences of immunosenescence in chronic kidney diseases].

Bamoulid J, Carron C, Crépin T, Saas P, Ducloux D.

Med Sci (Paris). 2015 May;31(5):484-6. doi: 10.1051/medsci/20153105008. Epub 2015 Jun 9. French. No abstract available.

23.

ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients.

Crepin T, Carron C, Roubiou C, Gaugler B, Gaiffe E, Simula-Faivre D, Ferrand C, Tiberghien P, Chalopin JM, Moulin B, Frimat L, Rieu P, Saas P, Ducloux D, Bamoulid J.

Am J Transplant. 2015 Apr;15(4):1028-38. doi: 10.1111/ajt.13092. Epub 2015 Mar 10.

24.

The need for minimization strategies: current problems of immunosuppression.

Bamoulid J, Staeck O, Halleck F, Khadzhynov D, Brakemeier S, Dürr M, Budde K.

Transpl Int. 2015 Aug;28(8):891-900. doi: 10.1111/tri.12553. Epub 2015 Mar 18. Review.

25.

Alloimmune responses and atherosclerotic disease after kidney transplantation.

Ducloux D, Courivaud C, Bamoulid J, Bisaccia V, Roubiou C, Crepin T, Gaugler B, Laheurte C, Rebibou JM, Chalopin JM, Saas P.

Transplantation. 2015 Jan;99(1):220-5. doi: 10.1097/TP.0000000000000346.

PMID:
25286052
26.

Polyclonal antithymocyte globulin and cardiovascular disease in kidney transplant recipients.

Ducloux D, Courivaud C, Bamoulid J, Crepin T, Chalopin JM, Tiberghien P, Saas P.

J Am Soc Nephrol. 2014 Jun;25(6):1349-56. doi: 10.1681/ASN.2013060663. Epub 2014 Feb 7.

27.

A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib.

Martino S, Daguindau E, Ferrand C, Bamoulid J, Hayette S, Nicolini FE, Capellier G, Deconinck E, Larosa F.

Leuk Res Rep. 2013 Mar 19;2(1):29-31. doi: 10.1016/j.lrr.2013.02.003. eCollection 2013.

28.

Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients.

Courivaud C, Bamoulid J, Chalopin JM, Gaiffe E, Tiberghien P, Saas P, Ducloux D.

J Infect Dis. 2013 May 15;207(10):1569-75. doi: 10.1093/infdis/jit064. Epub 2013 Feb 15.

PMID:
23417659
29.

Influence of fractalkine receptor gene polymorphisms V249I-T280M on cancer occurrence after renal transplantation.

Courivaud C, Bamoulid J, Loupy A, Deschamps M, Ferrand C, Simula-Faivre D, Tiberghien P, Chalopin JM, Legendre C, Thervet E, Borg C, Saas P, Ducloux D.

Transplantation. 2013 Mar 15;95(5):728-32. doi: 10.1097/TP.0b013e31827d61cb.

PMID:
23388733
30.

Subclinical Epstein-Barr virus viremia among adult renal transplant recipients: incidence and consequences.

Bamoulid J, Courivaud C, Coaquette A, Chalopin JM, Gaiffe E, Saas P, Ducloux D.

Am J Transplant. 2013 Mar;13(3):656-62. doi: 10.1111/ajt.12009. Epub 2013 Jan 17.

31.

Cytomegalovirus exposure, immune exhaustion and cancer occurrence in renal transplant recipients.

Courivaud C, Bamoulid J, Gaugler B, Roubiou C, Arregui C, Chalopin JM, Borg C, Tiberghien P, Woronoff-Lemsi MC, Saas P, Ducloux D.

Transpl Int. 2012 Sep;25(9):948-55. doi: 10.1111/j.1432-2277.2012.01521.x. Epub 2012 Jul 11.

32.

Rheumatoid purpura associated with toxocariasis.

Bellanger AP, Bamoulid J, Millon L, Chalopin JM, Humbert P.

Can Fam Physician. 2011 Dec;57(12):1413-4. No abstract available.

33.

[A rare cause of anemia in a chronic dialyzed patient].

Crépin T, Bamoulid J, Tunda A, Moskovtchenko P, Ducloux D.

Nephrol Ther. 2012 Apr;8(2):110-2. doi: 10.1016/j.nephro.2011.07.404. Epub 2011 Sep 28. French.

PMID:
21955392
34.

The COX-2 gene promoter polymorphism -765 delays CD4 T-cell reconstitution after lymphocyte depletion with antithymocyte globulins.

Courivaud C, Bamoulid J, Ferrand C, Tiberghien P, Chalopin JM, Saas P, Ducloux D.

Hum Immunol. 2011 Nov;72(11):1060-3. doi: 10.1016/j.humimm.2011.05.023. Epub 2011 Jul 8.

PMID:
21782872
35.

The interleukin-6 gene promoter polymorphism -174 and atherosclerotic events in overweight transplanted patients.

Bamoulid J, Courivaud C, Deschamps M, Gaugler B, Tiberghien P, Chalopin JM, Saas P, Ducloux D.

J Transplant. 2011;2011:803429. doi: 10.1155/2011/803429. Epub 2011 Jun 1.

36.

Thymic function, anti-thymocytes globulins, and cancer after renal transplantation.

Ducloux D, Bamoulid J, Courivaud C, Gaugler B, Rebibou JM, Ferrand C, Chalopin JM, Borg C, Tiberghien P, Saas P.

Transpl Immunol. 2011 Jul;25(1):56-60. doi: 10.1016/j.trim.2011.05.003. Epub 2011 May 19.

PMID:
21620972
37.

Significant increase in 1-year posttransplant renal arterial index predicts graft loss.

Loock MT, Bamoulid J, Courivaud C, Manzoni P, Simula-Faivre D, Chalopin JM, Kastler B, Ducloux D.

Clin J Am Soc Nephrol. 2010 Oct;5(10):1867-72. doi: 10.2215/CJN.01210210. Epub 2010 Jul 8.

38.

Influence of cyclooxygenase-2 (COX-2) gene promoter polymorphism at position -765 on skin cancer after renal transplantation.

Aubin F, Courivaud C, Bamoulid J, Loupy A, Deschamps M, Ferrand C, Le Corre D, Tiberghien P, Chalopin JM, Legendre C, Thervet E, Humbert P, Saas P, Ducloux D.

J Invest Dermatol. 2010 Aug;130(8):2134-6. doi: 10.1038/jid.2010.116. Epub 2010 May 6. No abstract available.

39.

Prolonged CD4 T cell lymphopenia increases morbidity and mortality after renal transplantation.

Ducloux D, Courivaud C, Bamoulid J, Vivet B, Chabroux A, Deschamps M, Rebibou JM, Ferrand C, Chalopin JM, Tiberghien P, Saas P.

J Am Soc Nephrol. 2010 May;21(5):868-75. doi: 10.1681/ASN.2009090976. Epub 2010 Mar 4.

40.

G-765C COX-2 gene promoter polymorphism and risk of atherosclerosis after kidney transplantation.

Courivaud C, Bamoulid J, Tiberghien P, Saas P, Chalopin JM, Ducloux D, Legendre C, Thervet E.

Transplantation. 2009 Sep 27;88(6):851-2. doi: 10.1097/TP.0b013e3181b4e938. No abstract available.

PMID:
19920789
41.

The case: a female with hyponatremia. Diagnosis: Postpartum panhypopituitarism (Sheehan syndrome).

Bamoulid J, Courivaud C, Kazory A, Bonneville JF, Ducloux D.

Kidney Int. 2009 Aug;76(3):351-2. doi: 10.1038/ki.2009.176. No abstract available.

42.

Influence of cyclooxygenase-2 (COX-2) gene promoter polymorphism -765 on graft loss after renal transplantation.

Courivaud C, Bamoulid J, Loupy A, Deschamps M, Ferrand C, Le Corre D, Tiberghien P, Chalopin JM, Legendre C, Thervet E, Saas P, Ducloux D.

Am J Transplant. 2009 Dec;9(12):2752-7. doi: 10.1111/j.1600-6143.2009.02830.x. Epub 2009 Sep 25.

43.

Pretransplant serum vitamin D levels and risk of cancer after renal transplantation.

Ducloux D, Courivaud C, Bamoulid J, Kazory A, Dumoulin G, Chalopin JM.

Transplantation. 2008 Jun 27;85(12):1755-9. doi: 10.1097/TP.0b013e318172cb2c.

PMID:
18580467
44.

[Immune monitoring of kidney transplant recipients: can markers predictive of over-immunosuppression be identified?].

Saas P, Courivaud C, Bamoulid J, Garnache-Ottou F, Seilles E, Ducloux D.

Ann Pharm Fr. 2008 Mar;66(2):115-21. doi: 10.1016/j.pharma.2008.03.004. Epub 2008 Jun 4. Review. French.

PMID:
18570910
45.

IL-6 promoter polymorphism -174 is associated with new-onset diabetes after transplantation.

Bamoulid J, Courivaud C, Deschamps M, Mercier P, Ferrand C, Penfornis A, Tiberghien P, Chalopin JM, Saas P, Ducloux D.

J Am Soc Nephrol. 2006 Aug;17(8):2333-40. Epub 2006 Jul 12.

46.

Relevance of Toll-like receptor-4 polymorphisms in renal transplantation.

Ducloux D, Deschamps M, Yannaraki M, Ferrand C, Bamoulid J, Saas P, Kazory A, Chalopin JM, Tiberghien P.

Kidney Int. 2005 Jun;67(6):2454-61.

Supplemental Content

Loading ...
Support Center